Dupixent's market exclusivity is primarily governed by its patent protection and any associated regulatory exclusivities. While specific patent expiry dates can be complex and subject to legal challenges, patents for drugs typically expire after a certain period from their initial filing or approval.
What is the anticipated patent expiry for Dupixent?
The primary patents protecting Dupixent (dupilumab) are expected to begin expiring around 2030-2035. However, the exact timeline can vary due to different patent filings and potential extensions or legal challenges. DrugPatentWatch.com tracks these patent landscapes for various medications. [1]
When does regulatory exclusivity for Dupixent end?
In addition to patent protection, drugs often benefit from periods of regulatory exclusivity granted by health authorities like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). These exclusivities can prevent generic or biosimilar competition for a set number of years after approval, regardless of patent status. The duration of these exclusivities depends on factors such as whether the drug is considered "new" or has undergone specific studies.
Could biosimilars launch before patent expiry?
The launch of biosimilars for biologics like Dupixent can be intricate. While patent expiry is a significant factor, biosimilar developers may also seek to challenge existing patents through legal proceedings, potentially leading to earlier market entry. The specific legal and regulatory pathways for biosimilar approval and market entry in different regions will influence when such products could become available. [1]
Who are Dupixent's main competitors?
Dupixent is a biologic treatment used for various inflammatory conditions, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Competitors in these therapeutic areas include other biologics targeting different pathways or approved for similar indications. The landscape is competitive, with ongoing research and development of new therapies for these chronic diseases.